Phosphodiesterase 6: Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: Phosphodiesterase 6 (PDE6)

NCBI ID: P13012

Phosphodiesterase 6 (PDE6)

Other Name(s): Phosphodiesterase 6 | PDE VI | Phosphodiesterase VI | PDEVI | PDE6

Phosphodiesterase 6: Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Phosphodiesterase 6 (PDE6) is an enzyme that is involved in the process of intracellular signaling. It is a critical enzyme in the production of various signaling molecules, including nitric oxide, which plays a crucial role in cardiovascular and neural function. PDE6 is also a drug target and has been identified as a potential biomarker for several diseases.

PDE6 is a non-specified subtype of phosphodiesterase, which is a family of enzymes that catalyze the removal of phosphate groups from other enzymes. These enzymes are involved in a wide range of cellular processes, including intracellular signaling, DNA replication, and metabolism. PDE6 is a 12-kDa protein that is expressed in many different tissues and cells, including muscle, heart, brain, and cancer cells.

PDE6 is involved in the production of various signaling molecules, including nitric oxide, which is a potent vasodilator that relaxes blood vessels and improves blood flow. Nitric oxide is important for the regulation of blood pressure, blood flow, and the delivery of oxygen to tissues . It is also involved in the regulation of pain perception and neurotransmitter release.

PDE6 is a drug target because of its involvement in the production of nitric oxide. Drugs that inhibit PDE6 have been shown to increase nitric oxide production and improve blood flow, which can be beneficial for treating a wide range of conditions, including cardiovascular disease, cancer , and neurodegenerative diseases.

In addition to its role in nitric oxide production, PDE6 is also a potential biomarker for several diseases. For example, PDE6 has been shown to be involved in the development and progression of cancer. Cancer cells typically have increased levels of PDE6 and decreased levels of PDE6, which allows them to maintain access to the nitric oxide produced by PDE6. This increase in PDE6 and decrease in PDE6 levels can contribute to the development and progression of cancer.

PDE6 has also been shown to be involved in the regulation of pain perception and neurotransmitter release. It is involved in the production of endogenous opioids, which are natural painkillers that help to regulate pain perception. PDE6 has also been shown to play a role in the regulation of neurotransmitter release, including the production of dopamine and serotonin.

In conclusion, PDE6 is an important enzyme that is involved in the production of nitric oxide and other signaling molecules. It is a potential drug target and has been shown to be involved in the development and progression of cancer, as well as the regulation of pain perception and neurotransmitter release. Further research is needed to fully understand the role of PDE6 in these processes and to develop effective treatments for these conditions.

Protein Name: Phosphodiesterase 6 (PDE6) (nonspecified Subtype)

The "Phosphodiesterase 6 (PDE6) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Phosphodiesterase 6 (PDE6) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets